GlassScriptPhysician profile
Scott L Aronson
NPI 1285655274
$8,031.14
in general payments reported to CMS, 2019-2025
35 companies · $1,784 in 2025
The $1,784 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $474 · 2021: $1,118 · 2022: $1,005 · 2023: $1,010 · 2024: $1,658 · 2025: $1,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,313 · Education: $99.00 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,313.07 |
| Education | $99.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,479.81 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $967.45 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $890.33 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $673.20 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Ironwood Pharmaceuticals, INC | $501.83 | 2019-2025 | Linzess |
| Pfizer INC. | $484.56 | 2019-2025 | |
| Qol Medical, LLC | $211.80 | 2019-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $208.53 | 2019-2025 | Ocaliva |
| Ardelyx, INC. | $201.32 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $186.63 | 2023-2025 | Omvoh |
| Braintree Laboratories, INC. | $178.41 | 2021-2025 | Suflave, Sutab |
| Phathom Pharmaceuticals, INC. | $164.21 | 2024-2025 | Voquezna |
| Allergan, INC. | $118.26 | 2019 | |
| Celgene Corporation | $100.20 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $83.44 | 2024-2025 | Zenpep |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $76.41 | 2023-2024 | Rebyota |
| Daiichi Sankyo INC. | $68.12 | 2020-2021 | |
| Gilead Sciences, INC. | $66.23 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $51.30 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $29.98 | 2021 | |
| Redhill Biopharma INC. | $29.02 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $28.55 | 2023 | |
| Capsovision, INC. | $28.50 | 2023 | Capsocam Plus |
| Meridian Bioscience INC. | $25.37 | 2024 | |
| Madrigal Pharmaceuticals | $23.56 | 2024 | Resmetirom |
| Sanofi-Aventis U.S. LLC | $20.70 | 2024 | |
| Celltrion USA INC. | $16.63 | 2025 | Vegzelma |
| Evoke Pharma, INC. | $16.51 | 2023 | Gimoti |
| Alfasigma USA, INC. | $16.44 | 2020 | |
| Organon LLC | $16.26 | 2023 | Renflexis |
| Astrazeneca Pharmaceuticals LP | $14.37 | 2019 | |
| Genzyme Corporation | $14.25 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.19 | 2025 | Givlaari |
| Echosens North America, INC. | $12.87 | 2019 | |
| Vivus LLC | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Aronson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.